Understanding Deceptive PBM Practices
Drug Topics
APRIL 9, 2024
In an interview at AAP 2024, Douglas Hoey, CEO of NCPA, talked about changing the pharmacy payment model and deceptive practices being employed by PBMs.
Drug Topics
APRIL 9, 2024
In an interview at AAP 2024, Douglas Hoey, CEO of NCPA, talked about changing the pharmacy payment model and deceptive practices being employed by PBMs.
STAT
APRIL 9, 2024
One of the country’s biggest life insurers is venturing into genetic testing, an area that’s historically been a minefield for that industry, in a purported effort to keep its members alive longer. MassMutual announced Tuesday that it’s offering many of its 4.2 million policyholders free genetic risk assessments for eight common diseases, like heart disease, type 2 diabetes, and breast cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
APRIL 9, 2024
Brian Rakers, senior vice president of distribution and member support at Pharmacists Mutual Insurance Group, talked cybersecurity during a session at AAP 2024.
Fierce Healthcare
APRIL 9, 2024
Healthcare company Bayer has tapped Google for its cloud and artificial intelligence capabilities to build new tech products to assist radiologists. | Bayer wants to pair its radiology, healthcare regulator and clinical data handling expertise with Google's tech muscle and ongoing work in generative AI to speed up innovation in media imaging.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
APRIL 9, 2024
Abrysvo is currently approved to treat RSV-associated lower respiratory tract disease in adults aged 60 years and older, and in infants through the immunization of pregnant individuals.
Pharmacy Times
APRIL 9, 2024
In March 2024, the label for bempedoic acid was expanded to reduce cardiovascular risk and expand the low-density lipoprotein-C (LDL-C) lowering in both primary and secondary prevention patients.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
APRIL 9, 2024
Teenagers don’t get arthritis. That’s what Tiffany Peterson kept hearing as that dreadful feeling in her 17-year-old wrists and knees grew excruciating. So she tried to ignore it, popping over-the-counter pain medicines and keeping her head in science textbooks, her hands full in the evening with extracurriculars and a half dozen younger siblings to care for.
Fierce Healthcare
APRIL 9, 2024
All 11 of Massachusetts’ federal legislators are calling on regulators to keep a short leash on UnitedHealth Group’s proposed acquisition of Steward Health Care’s physician group, even if that mean | The financial jeopardy of Steward's remaining hospitals can't override the long-term cost and quality harms that would likely follow UnitedHealth Group's acquisition of yet another large physician practice, wrote all 11 of the state's federal legislators in a recent letter to reg
STAT
APRIL 9, 2024
The numbers are in, and biotech startups recently closed out their best fundraising quarter in two years, signaling that the industry downturn may soon be a thing of the past. Venture-backed biopharma companies raised $6.8 billion in the first three months of the year, according to early data compiled by HSBC. That’s the largest amount raised since the first half of 2022.
Fierce Pharma
APRIL 9, 2024
About 15 years ago, Carl Ola Landgren, M.D. Ph.D., noticed an encouraging yet potentially concerning trend in the treatment of multiple myeloma. | At an FDA advisory committee meeting this Friday, two teams will present their studies examining the utility of minimal residue disease (MRD) as a potentially approvable endpoint in multiple myeloma. For this report, Fierce Pharma spoke with experts to learn about what's at stake, including the need to bring new treatments to patients earlier.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
APRIL 9, 2024
Virginia Gov. Glenn Youngkin vetoed a bill that would have created a new entity for capping the cost of prescription drugs, an increasingly popular tactic that a growing number of state lawmakers around the U.S. are exploring to control their budgets. The Prescription Drug Affordability Board, which was designed to function like a rate-setting authority, would have set upper payment limits used to cap the cost of a select number of medicines for Virginia residents who are covered by a state or l
Fierce Healthcare
APRIL 9, 2024
Supplemental benefits administrator Avesis and Elevance Health subsidiary Amerigroup Georgia have teamed up with Uber Health in a pilot project to tackle the state's maternal health crisis.
Fierce Pharma
APRIL 9, 2024
Even as Novartis rolls ahead with a global restructuring campaign targeting thousands of job cuts, the Swiss drug giant has blueprinted several hundred layoffs in its development organizational uni | Even as Novartis rolls ahead with a global restructuring campaign targeting thousands of job cuts, the Swiss drug giant has blueprinted several hundred layoffs in its development organizational unit.
STAT
APRIL 9, 2024
The team behind Karuna Therapeutics, which was recently snapped up in a multibillion-dollar deal, on Tuesday rolled out another neuropsychiatric-focused biotech, called Seaport Therapeutics. The new company will be led by Daphne Zohar, the founding CEO of the biotech startup foundry PureTech Health, which helped launch both Karuna and Seaport.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
APRIL 9, 2024
Great Ormond Street Hospital is applying for the license to a gene therapy for rare disease ADA-SCID that was abandoned by a biotech developer on commercial grounds.
Fierce Healthcare
APRIL 9, 2024
Consumers expect a simple and easy digital experience, and health plans have plenty of room to improve on that front, according to a new report. | Consumers expect a simple and easy digital experience, and health plans have plenty of room to improve on that front, according to a new report.
pharmaphorum
APRIL 9, 2024
Navigating the complex path towards commercialising In Vitro Diagnostics (IVDs) can be challenging. Learn more about the intricate process involved in bringing early diagnostic tools to market.
Fierce Pharma
APRIL 9, 2024
Though gene therapy manufacturing specialist Ascend Advanced Therapies just launched a little more than a year ago, the CDMO is already on the hunt to expand. | Ascend, which bills itself as a “total solutions gene therapy development partner,” has picked up the manufacturing team and site of Beacon Therapeutics in Alachua, Florida. As part of the deal, Ascend has also agreed to a long-term partnership with Beacon to produce its ocular gene therapies for clinical and commercial use.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
APRIL 9, 2024
Bayer enlists the aid of Google Cloud to develop its AI platform for radiologists, adding genAI capabilities
STAT
APRIL 9, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with an update on the biotech market, a look at the future of genome editing, and the evolving definition of “insider trading.
pharmaphorum
APRIL 9, 2024
On today's episode of the podcast CEO and co-founder of 908 Devices Kevin Knopp joins as guest, discussing how such acceleration is by virtue of technological advancements, including the buzzword artificial intelligence (AI) and machine learning when it comes to bioprocessing.
Fierce Pharma
APRIL 9, 2024
Researchers plan to run biomarker analyses of patients in the KEYLYNK-008 trial to see whether any subsets may benefit from the addition of Lynparza.
pharmaphorum
APRIL 9, 2024
A UK report has found that people from minority ethnic backgrounds face an average delay of a year between first noticing symptoms and gaining a diagnosis, which is more than twice as long as white people.
STAT
APRIL 9, 2024
WASHINGTON — The company responsible for a global recall of sleep apnea machines will be barred from resuming production at U.S. facilities until it meets a number of safety requirements, under a long-awaited settlement announced Tuesday by federal officials. Philips will be required to overhaul its manufacturing and quality control systems and hire independent experts to vet the changes, according to a court order announced by the U.S.
pharmaphorum
APRIL 9, 2024
The team that brought you Karuna, recently sold to Bristol-Myers Squibb for $14 billion, has set up a neuropsychiatry-focused biotech called Seaport Therapeutics
Pharmacy Times
APRIL 9, 2024
Social determinants of health can worsen mental health disorders such as depression, but the effect of depression can also negatively impact social determinants of health.
PioneerRx
APRIL 9, 2024
Graduating from pharmacy school is no small feat. After years of study and endless rounds of rotations, residencies, and internships, you’re finally able to.
pharmaphorum
APRIL 9, 2024
People with Cushing’s syndrome can sometimes take years to get a diagnosis, but a new project hopes to shorten that timeline with the help of artificial intelligence.
Fierce Healthcare
APRIL 9, 2024
Aegis Ventures has launched a digital health innovation collaborative with the backing of nine founding health systems. | The new Digital Consortium aims to put health systems at the center of digital health innovation to help address healthcare’s most pressing quality, equity and cost challenges. These health systems will co-develop, invest in and deploy health tech solutions alongside Aegis.
Pharmacy Times
APRIL 9, 2024
Challenges in treating insomnia in special groups and resistant cases, and ways for pharmacists to improve outcomes.
Fierce Pharma
APRIL 9, 2024
Medication adherence is a large and growing challenge for pharma companies, healthcare providers and the patients they serve. In the U.S. | Research shows that 20% of patients have failed to fill a script in the past, and one-third aren’t confident managing their illness. Engaging patients from the moment a drug is prescribed can help.
Pharmacy Times
APRIL 9, 2024
Pharmacists should be well educated on prescription digital therapeutics to better educate patients on software in comparison to traditional pharmacological products.
European Pharmaceutical Review
APRIL 9, 2024
Research published in Biosensors reports the strong potential of using 3D printed substrates in bacterial analysis. The study by Childs et al. utilised a rapid 3D printed µbiochamber with a laser-ablated interdigitated electrode. This system was developed for biofilm analysis of Pseudomonas aeruginosa , Acinetobacter baumannii and Bacillus subtilis using electrochemical biological impedance spectroscopy (EBIS) across a four-hour spectrum.
Let's personalize your content